LeMaitre Vascular, Inc. (LMAT) Fair Value 2026

LMAT · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.3 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-27, LeMaitre Vascular, Inc. (LMAT) trades at $79.67, versus a $43.67 median fair value across its 11 active models — 45.2% below the current price. QOC: 9.3/10. Value Trap Risk: 18/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $62.76.

Key Facts

Ticker
LMAT
Price
$79.67
Quality Score
9.3/10
Value Trap Risk
18/100
Models Active
11/13
Last Updated
Strength: Quality Score of 9.3/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is LeMaitre Vascular, Inc. (LMAT) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, LeMaitre Vascular, Inc. (LMAT) appears overvalued as of : the median of 11 independent fair value estimates is $43.67, 45.2% below the current price of $79.67. Estimates range from $19.70 to $116.09. LMAT scores 9.3/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. LMAT’s -45.2% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -36.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy LeMaitre Vascular, Inc. Stock in 2026? →

What Fair Value Does Each Model Give LMAT?

11 Intrinsic Value Models vs. Current Price ($79.67)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $62.76 -21.2%
Intrinsic · High Conviction
 $19.70 -75.3%
Ensemble · Medium Conviction
 $43.67 -45.2%
Scenario · High Conviction
 $62.10 -22.1%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is LMAT's Fair Value Range?

Spread across 11 independent models · $19.70 to $116.09

CirclFi's 11 active models place LeMaitre Vascular, Inc. (LMAT) between $19.70 and $116.09 per share, a spread of 221% of the median. The median of that range — $43.67 — is the fair value CirclFi publishes for LMAT, against a current price of $79.67.

Low · EPVHigh · Regime Cross
$19.70median $43.67$116.09
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$19.70
Most bullish modelRegime Cross-Sectional$116.09
Model agreement1 bullish · 10 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for LMAT. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on LMAT, not a CirclFi price target. How each model works →

What Is LeMaitre Vascular, Inc. (LMAT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, LeMaitre Vascular, Inc.'s intrinsic value is estimated at $43.67. Trading at its current price of $79.67, the valuation engine raises significant caution: 10 of 11 models flag downside risk, projecting a median implied return of -45.2%. Model dispersion is worth noting: Regime Cross targets $116.09 (+45.7%), versus EPV at $19.70 (-75.3%). This +121.0% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About LMAT?

11 of 13 models are currently active for LMAT. Of these, 1 model suggests upside while 10 models suggest overvaluation. Taken together, their median fair value for LMAT is $43.67 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $62.76 on its own, implying -21.2% downside from the current price. See which stocks rank higher →

How Does LMAT Rank in Medical Instruments & Supplies?

Among 55 Medical Instruments & Supplies stocks, LMAT ranks #3 by Quality of Company score. CirclFi's QOC score of 9.3/10 evaluates 32 fundamental signals. A score of 9.3 places LMAT in the top tier.

See all Most Undervalued Medical Instruments & Supplies Stocks →

LeMaitre Vascular, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is LMAT a Value Trap?

CirclFi's Value Trap algorithm assigns LMAT a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for LeMaitre Vascular, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, LeMaitre Vascular, Inc. earns a quality score of 9.3/10. This exceptional rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +121.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LMAT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LMAT's 11 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy LeMaitre Vascular, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

9 related Medical Instruments & Supplies stocks with 13-model coverage

RMDResMed Inc.QOC 9.4ATRAptarGroup, Inc.QOC 8.9ISRGIntuitive Surgical, Inc.QOC 9.4MMSIMerit Medical Systems, Inc.QOC 8.7NNNNAnbio BiotechnologyQOC 2.4WSTWest Pharmaceutical Services, Inc.QOC 8.7ATRCAtriCure, Inc.QOC 7.8BAXBaxter International Inc.QOC 6.3LUCYLucyd, IncQOC 5.6

Read investment analysis: RMD · ATR · ISRG · MMSI · NNNN · WST · ATRC · BAX · LUCY

Which Other Stocks Have a Similar Quality Score to LMAT?

7 companies across all industries closest to LMAT’s Quality of Company score of 9.3/10.

PHParker-Hannifin CorporationQOC 9.3BMIBadger Meter, Inc.QOC 9.3AMPAmeriprise Financial, Inc.QOC 9.3BZKanzhun LimitedQOC 9.3AZNAstraZeneca PLCQOC 9.3NEMNewmont CorporationQOC 9.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PH · BMI · AMP · BZ · AZN · NEM · NVDA

Where Does LMAT Sit in CirclFi's Medical Instruments & Supplies Rankings?

LMAT is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About LeMaitre Vascular, Inc.’s Valuation?

What is LeMaitre Vascular, Inc.'s intrinsic value in 2026?

CirclFi puts LeMaitre Vascular, Inc. (LMAT)'s intrinsic value at $43.67 — the median of 11 independent model estimates as of 2026-08-27, ranging from $19.70 to $116.09. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $62.76 on its own. The Quality of Company score is 9.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LMAT overvalued or undervalued right now?

At $79.67, 1 of 11 active models suggest LMAT may be undervalued, while 10 indicate potential overvaluation. The median of all 11 fair value estimates is $43.67, 45.2% below the current price of $79.67 — a consensus view that LMAT is overvalued. The assessment depends on which methodology best fits LeMaitre Vascular, Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 9.3 mean for LMAT?

LeMaitre Vascular, Inc.'s QOC of 9.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on LMAT?

CirclFi analyzes LMAT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on LMAT?

Of the 11 models currently active on LMAT, Regime Cross-Sectional is the most bullish at $116.09 per share, and Earnings Power Value (EPV) is the most bearish at $19.70. CirclFi's published fair value for LMAT is the median of that range, $43.67, not either extreme. The gap between the two ends equals 221% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is LMAT a value trap in 2026?

LeMaitre Vascular, Inc.'s Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, LeMaitre Vascular, Inc. (LMAT) has a median fair value of $43.67 — 45.2% below the current price of $79.67 — as of 2026-08-27.” Source: circlfi.com/stock/LMAT/ · Methodology
Primary sources for this LMAT valuation
  • Financial statements: LeMaitre Vascular, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001158895) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LMAT as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on LMAT.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for LMAT Unlock All 11 — $39/mo